Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.

ABSTRACT:

Background

The Androgen Receptor (AR) pathway is crucial in driving the progression of prostate cancer (PCa) to an advanced state. Despite the introduction of second-generation AR antagonists, such as enzalutamide, majority of patients develop resistance. Several mechanisms of resistance have been identified, including the constitutive activation of the AR pathway, the emergence of AR spliced variants, and the influence of other signalling pathways. The Serum Response Factor (SRF) was previously identified as a possible player of resistance involved in a crosstalk with the AR signalling pathway. Elevated SRF levels in PCa patients were associated with disease progression and resistance to enzalutamide. However, the molecular mediators of the crosstalk between SRF and AR still need

SUBMITTER: Azam H 

PROVIDER: S-EPMC11642960 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature